We are looking for women who are within six weeks of giving birth to help us learn how doula support and spending time in nature can lower stress, improve sleep, and support overall wellbeing. This study looks at ways to help mothers recover and thrive during the early weeks after giving birth.
In this study we want to learn how babies are affected when their mothers have a viral infection during pregnancy. To do this, we will collect blood samples from pregnant women who have viral infections (like COVID-19) and those who do not.
This study wants to learn how equol, a supplement made from soy, affects blood vessel health in postmenopausal women with chronic kidney disease (CKD). This study wants to see if taking equol for 12 weeks can help blood vessels work better.
This study wants to learn more about heart and brain health of people with and without endometriosis.
This study wants to learn how late menopause affects women. This study wants to see whether diet education, lifestyle changes, and medication can help women feel healthier. We are looking for women ages 45 to 55 who are in late menopause to join.
This study wants to find out how differences in our DNA might affect how birth control works in our bodies and which side effects they may experience.
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.
The purpose of this study is to evaluate the safety and efficacy of the three-drug combination of tucatinib, trastuzumab, and eribulin in patients with de novo and recurrent unresectable metastatic HER-2/neu positive breast cancer as assessed by ORR, PFS and OS after prior treatment with a taxane, trastuzumab, and T-DM1.
We want to learn how nightmares from trauma or posttraumatic stress disorder (PTSD) affect heart and artery health in women. We also want to see if a treatment called NightWare, which is used on a smartwatch, can help women with these nightmares sleep better and improve their heart and artery health.
This study wants to learn more about how estrogen affects women's reproductive hormones and system.
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the a...
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (...
This study wants to learn how working at night or outside normal daytime hours affects women’s heart and reproductive health in women. We are looking for women who work night shifts, both day and night shifts, or only daytime shifts to see how different work hours may affect heart and reproductive health.
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
We are looking for couples that have had two or more pregnancy losses with no known cause. We want to find out if genetics might be a reason for recurrent pregnancy loss (RPL).
This study will provide pilot data examining suction as a mechanism of IUD displacement with menstrual cup use. We hypothesize that manufacturer-recommended menstrual cup insertion and removal by breaking the seal will result in 15% rate of IUD displacement/expulsion. We will also use this data to explore variables associated with IUD displacement and menstrual cup use. By examining the role of su...
This study is for women who are about to start IVF. It will test if the medicine, Orilissa, which helps with endometriosis symptoms, will affect fertility.
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
This study wants to collect medical information from people with Turner Syndrome at clinics across the country to learn more about the condition. We are gathering this data in a national registry to help improve the health and care for people with Turner Syndrome in the future.
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive de...
In this study we want to learn if a medicine approved for diabetes and weight loss called Ozempic® and Wegovy® (semaglutide) can help improve the frequency of periods and the way the body uses sugar in women with polycystic ovary syndrome (PCOS).
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with fulvestrant or trastuzumab. Phase 1a (Part A) will investigate escalating doses of OKI-219 monotherapy, and Phase 1b will investigate OKI-219 (at a tolerated dose det...